当前位置: 首页 >> 检索结果
841. 10-year follow-up results of the European Achalasia Trial: a multicentre randomised controlled trial comparing pneumatic dilation with laparoscopic Heller myotomy.
作者: Guy Boeckxstaens.;Stefanie Elsen.;Ann Belmans.;Vito Annese.;Albert J Bredenoord.;Olivier R Busch.;Mario Costantini.;Uberto Fumagalli.;André J P M Smout.;Jan Tack.;Tim Vanuytsel.;Giovanni Zaninotto.;Renato Salvador.
来源: Gut. 2024年73卷4期582-589页
As achalasia is a chronic disorder, long-term follow-up data comparing different treatments are essential to select optimal clinical management. Here, we report on the 10-year follow-up of the European Achalasia Trial comparing endoscopic pneumodilation (PD) with laparoscopic Heller myotomy (LHM).
842. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.
作者: Jing Han Hong.;Chern Han Yong.;Hong Lee Heng.;Jason Yongsheng Chan.;Mai Chan Lau.;Jianfeng Chen.;Jing Yi Lee.;Abner Herbert Lim.;Zhimei Li.;Peiyong Guan.;Pek Lim Chu.;Arnoud Boot.;Sheng Rong Ng.;Xiaosai Yao.;Felicia Yu Ting Wee.;Jeffrey Chun Tatt Lim.;Wei Liu.;Peili Wang.;Rong Xiao.;Xian Zeng.;Yichen Sun.;Joanna Koh.;Xiu Yi Kwek.;Cedric Chuan Young Ng.;Poramate Klanrit.;Yaojun Zhang.;Jiaming Lai.;David Wai Meng Tai.;Chawalit Pairojkul.;Simona Dima.;Irinel Popescu.;Sen-Yung Hsieh.;Ming-Chin Yu.;Joe Yeong.;Sarinya Kongpetch.;Apinya Jusakul.;Watcharin Loilome.;Patrick Tan.;Jing Tan.;Bin Tean Teh.
来源: Gut. 2024年73卷6期966-984页
Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify potential therapeutic targets in different subtypes of CCA through enhancer profiling.
844. Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
作者: Rui Li.;Xuefei Liu.;Xudong Huang.;Di Zhang.;Ziming Chen.;Jialiang Zhang.;Ruihong Bai.;Shaoping Zhang.;Hongzhe Zhao.;Zilan Xu.;Lingxing Zeng.;Lisha Zhuang.;Shujuan Wen.;Shaojia Wu.;Mei Li.;Zhixiang Zuo.;Junzhong Lin.;Dongxin Lin.;Jian Zheng.
来源: Gut. 2024年73卷3期470-484页
Metastasis is the major cause of cancer death. However, what types of heterogenous cancer cells in primary tumour and how they metastasise to the target organs remain largely undiscovered.
845. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.
作者: Jiaying Zhu.;Chuqing Sun.;Min Li.;Guoru Hu.;Xing-Ming Zhao.;Wei-Hua Chen.
来源: Gut. 2024年73卷7期1087-1097页
We aim to compare the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the gut microbiota through longitudinal analysis.
846. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
作者: Albert J Bredenoord.;Evan S Dellon.;Ikuo Hirano.;Alfredo J Lucendo.;Christoph Schlag.;Xian Sun.;Lila Glotfelty.;Leda Mannent.;Jennifer Maloney.;Elizabeth Laws.;Eric Mortensen.;Arsalan Shabbir.
来源: Gut. 2024年73卷3期398-406页
To assess the effect of long-term dupilumab on histological, symptomatic and endoscopic aspects of eosinophilic oesophagitis (EoE) in adolescent and adult patients with and without prior use of swallowed topical corticosteroids (STC) or prior inadequate response, intolerance or contraindication to STC.
848. Understanding the malignant potential of gastric metaplasia of the oesophagus and its relevance to Barrett's oesophagus surveillance: individual-level data analysis.
作者: Emily L Black.;Emma Ococks.;Ginny Devonshire.;Alvin Wei Tian Ng.;Maria O'Donovan.;Shalini Malhotra.;Monika Tripathi.;Ahmad Miremadi.;Adam Freeman.;Hannah Coles.; .;Rebecca C Fitzgerald.
来源: Gut. 2024年73卷5期729-740页
Whether gastric metaplasia (GM) of the oesophagus should be considered as Barrett's oesophagus (BO) is controversial. Given concern intestinal metaplasia (IM) may be missed due to sampling, the UK guidelines include GM as a type of BO. Here, we investigated whether the risk of misdiagnosis and the malignant potential of GM warrant its place in the UK surveillance.
|